Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-6 Sublingual Tablet in Acute Ischemic Stroke (Phase III)
CTR20252105Phase 3Active
- Sponsor
- Nanjing NeuroDawn Pharmaceutical
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cilostazol + dexborneol in ischemic stroke, sponsored by Nanjing NeuroDawn Pharmaceutical. Started Jul 2025; status: active.
02
Drugs
cilostazol + dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20252105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252105.